193 related articles for article (PubMed ID: 33563246)
21. Clinical characteristics of second primary cancer in colorectal cancer patients: the impact of colorectal cancer or other second cancer occurring first.
Sun LC; Tai YY; Liao SM; Lin TY; Shih YL; Chang SF; Huang CW; Chan HM; Huang CJ; Wang JY
World J Surg Oncol; 2014 Mar; 12():73. PubMed ID: 24678904
[TBL] [Abstract][Full Text] [Related]
22. Trends in epidemiology, treatment, and survival of hepatocellular carcinoma patients between 1998 and 2009: an analysis of 1066 cases of a German HCC Registry.
Weinmann A; Koch S; Niederle IM; Schulze-Bergkamen H; König J; Hoppe-Lotichius M; Hansen T; Pitton MB; Düber C; Otto G; Schuchmann M; Galle PR; Wörns MA
J Clin Gastroenterol; 2014 Mar; 48(3):279-89. PubMed ID: 24045276
[TBL] [Abstract][Full Text] [Related]
23. Effect of menopausal status on the survival and recurrence of sex-classified hepatocellular carcinoma after liver resection: a case-matched study with propensity score matching.
Zhang W; Liu F; Huang J; Guo X; Dong W; Wei S; Li L; Zhu X; Zhou W; Liu H
Aging (Albany NY); 2020 Nov; 12(24):25895-25915. PubMed ID: 33232278
[TBL] [Abstract][Full Text] [Related]
24. Improved Survival of Hepatocellular Carcinoma Patients Diagnosed with a Dedicated Screening Programme-a Propensity Score Adjusted Analysis.
Chinnaratha MA; Campbell K; Mathias R; McCormick RJ; Woodman RJ; Wigg AJ
J Gastrointest Cancer; 2019 Dec; 50(4):888-893. PubMed ID: 30345486
[TBL] [Abstract][Full Text] [Related]
25. Second primary cancers in patients with hepatocellular carcinoma: a nationwide cohort study in Taiwan.
Wu WC; Chen YT; Hwang CY; Su CW; Li SY; Chen TJ; Liu CJ; Kao WY; Chao Y; Lin HC; Wu JC
Liver Int; 2013 Apr; 33(4):616-23. PubMed ID: 23331767
[TBL] [Abstract][Full Text] [Related]
26. Race/ethnicity-specific disparities in cancer incidence, burden of disease, and overall survival among patients with hepatocellular carcinoma in the United States.
Ha J; Yan M; Aguilar M; Bhuket T; Tana MM; Liu B; Gish RG; Wong RJ
Cancer; 2016 Aug; 122(16):2512-23. PubMed ID: 27195481
[TBL] [Abstract][Full Text] [Related]
27. Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study.
Costentin CE; Layese R; Bourcier V; Cagnot C; Marcellin P; Guyader D; Pol S; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Riachi G; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Blanc JF; Abergel A; Serfaty L; Mallat A; Grangé JD; Attali P; Bacq Y; Wartelle C; Dao T; Thabut D; Pilette C; Silvain C; Christidis C; Nguyen-Khac E; Bernard-Chabert B; Zucman D; Di Martino V; Sutton A; Letouzé E; Imbeaud S; Zucman-Rossi J; Audureau E; Roudot-Thoraval F; Nahon P;
Gastroenterology; 2018 Aug; 155(2):431-442.e10. PubMed ID: 29729258
[TBL] [Abstract][Full Text] [Related]
28. Prognostic factors of spontaneously ruptured hepatocellular carcinoma.
Han XJ; Su HY; Shao HB; Xu K
World J Gastroenterol; 2015 Jun; 21(24):7488-94. PubMed ID: 26139994
[TBL] [Abstract][Full Text] [Related]
29. King's score as a novel prognostic model for patients with hepatitis B-associated hepatocellular carcinoma.
Pang Q; Bi JB; Xu XS; Liu SS; Zhang JY; Zhou YY; Qu K; Liu C
Eur J Gastroenterol Hepatol; 2015 Nov; 27(11):1337-46. PubMed ID: 26275082
[TBL] [Abstract][Full Text] [Related]
30. Natural History of T1N0M0 Hepatocellular Carcinoma: Large-Scale Study in the United States.
Al-Shamsi HO; Abdel-Wahab R; Hassan MM; Shalaby AS; Dahbour I; Lacin S; Mahvash A; Odisio BC; Murthy R; Avritscher R; Abdelsalam ME; Rashid A; Vauthey JN; Aloia TA; Conrad C; Chun YS; Krishnan S; Das P; Koay EJ; Amin HM; Yao JC; Kaseb AO
Oncology; 2017; 93(4):233-242. PubMed ID: 28683459
[TBL] [Abstract][Full Text] [Related]
31. Antiviral therapy improves post-operative survival outcomes in patients with HBV-related hepatocellular carcinoma of less than 3 cm - A retrospective cohort study.
Wang ZY; Tao QF; Wang ZH; Lin KY; Huang G; Yang Y; Zhou WP; Lau WY
Am J Surg; 2020 Apr; 219(4):717-725. PubMed ID: 31266631
[TBL] [Abstract][Full Text] [Related]
32. Favorable survival time provided with radioembolization in hepatocellular carcinoma patients with and without portal vein thrombosis.
Ozkan ZG; Poyanli A; Ucar A; Kuyumcu S; Akyuz F; Keskin S; Saglam S; Yilmaz E; Karaca C; Turkmen C
Cancer Biother Radiopharm; 2015 Apr; 30(3):132-8. PubMed ID: 25760644
[TBL] [Abstract][Full Text] [Related]
33. Pretreatment Inflammation-Based Markers Predict Survival Outcomes in Patients with Early Stage Hepatocellular Carcinoma After Radiofrequency Ablation.
Chu MO; Shen CH; Chang TS; Xu HW; Yen CW; Lu SN; Hung CH
Sci Rep; 2018 Nov; 8(1):16611. PubMed ID: 30413724
[TBL] [Abstract][Full Text] [Related]
34. Improved survival with radiotherapy in hepatocellular carcinoma with major vascular invasion: A propensity-matched analysis of Surveillance, Epidemiology, and End Results database.
Lin Q; Huang X; Zhong C; Luo T; Zeng X; Chen S
Cancer Med; 2019 Feb; 8(2):515-526. PubMed ID: 30656831
[TBL] [Abstract][Full Text] [Related]
35. The impact of liver resection on survival outcomes of hepatocellular carcinoma patients with extrahepatic metastases: A propensity score matching study.
Mao K; Yan Y; Zhang J; Wang J; Wang R; Ling X; Liu Y; Lau WY; Jiang S; Liu J; Xiao Z
Cancer Med; 2018 Sep; 7(9):4475-4484. PubMed ID: 30117307
[TBL] [Abstract][Full Text] [Related]
36. Effects of adjuvant traditional Chinese medicine therapy on long-term survival in patients with hepatocellular carcinoma.
Liu X; Li M; Wang X; Dang Z; Yu L; Wang X; Jiang Y; Yang Z
Phytomedicine; 2019 Sep; 62():152930. PubMed ID: 31128485
[TBL] [Abstract][Full Text] [Related]
37. Association of Addition of Ablative Therapy Following Transarterial Chemoembolization With Survival Rates in Patients With Hepatocellular Carcinoma.
English K; Brodin NP; Shankar V; Zhu S; Ohri N; Golowa YS; Cynamon J; Bellemare S; Kaubisch A; Kinkhabwala M; Kalnicki S; Garg MK; Guha C; Kabarriti R
JAMA Netw Open; 2020 Nov; 3(11):e2023942. PubMed ID: 33151315
[TBL] [Abstract][Full Text] [Related]
38. No apparent benefit of preemptive sorafenib therapy in liver transplant recipients with advanced hepatocellular carcinoma on explant.
Satapathy SK; Das K; Kocak M; Helmick RA; Eason JD; Nair SP; Vanatta JM
Clin Transplant; 2018 May; 32(5):e13246. PubMed ID: 29577449
[TBL] [Abstract][Full Text] [Related]
39. A Modified Model for Assessment for Retreatment with Transarterial Chemoembolization in Chinese Hepatocellular Carcinoma Patients.
Chen L; Ni CF; Chen SX; Cao JM; Zhu HD; Guo JH; Zhu GY; Zhong BY; Ding W; He SC; Deng G; Teng GJ
J Vasc Interv Radiol; 2016 Sep; 27(9):1288-1297. PubMed ID: 27013402
[TBL] [Abstract][Full Text] [Related]
40. Comparison of survival of patients with BCLC stage A hepatocellular carcinoma after hepatic resection or transarterial chemoembolization: a propensity score-based analysis.
Guo Z; Zhong JH; Jiang JH; Zhang J; Xiang BD; Li LQ
Ann Surg Oncol; 2014 Sep; 21(9):3069-76. PubMed ID: 24728740
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
